| Trial Name: |
PFIZ 1Y03
|
| Intro: |
A Multicenter, Open Label, Noncomparative Phase I-II Clinical and Pharmacokinetic Study of Oral PD0325901 in Patients with Advanced Cancer |
| Condition: |
|
| Description: |
This study will determine the safety profile including dose-limiting toxicities of oral PD0325901. Patients will receive oral PD0325901 once daily for 21 consecutive days followed by a 1-week holiday. Treatment cycles will repeat every 28 days. |
| Criteria: |
- Patients must be at least 18 years of age
- Patients must have tumor accessible for biopsy and willingness to undergo baseline and post-treatment biopsy
- Patients must have biopsiable breast cancer, colorectal cancer, NSCLC or melanoma proven histologically or cytologically at original diagnosis, refractory to treatment, or for which no standard treatments exist
- Patients must have adequate bone marrow, liver and kidney function
- Patients must not be receiving ongoing radiation therapy, or prior radio-, cytotoxic, immunotherapy, biologic therapy, or molecular targeted therapies within 4 weeks prior to registration or hormonal therapy within 2 weeks prior to registration.
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back